Agenus (AGEN) Q2 2025 earnings summary

Executive summary

• Colorectal cancer incidence is rising, especially among younger adults, with limited effective treatments for late-stage patients; BOT/BAL immunotherapy shows promising long-term survival and quality of life improvements over standard chemotherapy.

• Entered into an asset purchase agreement to sell manufacturing operations to Zydus for $75M upfront, up to $50M in contingent payments, and a $16M equity investment, with closing expected in Q3 2025.

• Regulatory alignment secured for a streamlined two-arm Phase 3 BATTMAN trial for BOT/BAL, expected to start globally in Q4 2025.

• Strategic collaborations and prudent financial management, including partnerships with Zydus and Noetik AI, position the company for continued advancement and broader applications.

• Regulatory delays and traditional trial paradigms remain barriers to timely patient access to innovative therapies.

Financial highlights

• Q2 YTD 2025 revenue was $49.8M, mainly from non-cash royalty revenue, with a net loss of $53.3M and operating loss of $30.0M.

• Cash and cash equivalents at June 30, 2025, were $9.5M–$20.2M, with a $91M capital infusion from Zydus expected in Q3 2025.

• Research and development expenses decreased 40% year-over-year to $48.2M for the six months ended June 30, 2025.

• Raised $18.6M from at-the-market equity offerings in the first half of 2025, with an additional $5.2M post-quarter.

• Gross margin remains high due to non-cash royalty revenue; cost of service revenue was $0.4M for the six months ended June 30, 2025.

Outlook and guidance

• BATTMAN Phase 3 trial for BOT/BAL in refractory MSS CRC to launch globally in Q4 2025, enrolling 834 patients with rapid recruitment anticipated.

• $91M capital infusion from Zydus expected to satisfy liquidity needs through 2026, but additional funding required for ongoing operations and product launches.

• Anticipates significant clinical data presentations and expanded evidence for BOT/BAL in multiple tumor types in 2H 2025.

• The company aims for accelerated approval pathways and is actively engaging with regulators to expedite patient access.

• Ongoing negotiations for additional funding and commercial partnerships beyond North America, Europe, and Japan.